mitoxantrone has been researched along with Cardiomyopathies in 22 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a previous dose-finding trial, in previously treated patients with metastatic breast cancer (MBC), we showed that the combination of Mitoxantrone (M) and Paclitaxel (P) may be an interesting (response rate: 69%) and well-tolerated regimen." | 9.11 | Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research. ( Acito, L; Angiona, S; Bilancia, D; Di Costanzo, F; Gasperoni, S; Giustini, L; Manzione, L; Mazzoni, F, 2004) |
| "The review assessed the efficacy and tolerability of mitoxantrone in patients with neuromyelitis optica spectrum disorder (NMOSD)." | 9.01 | Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. ( Enriquez, CAG; Espiritu, AI; Pasco, PMD, 2019) |
| "Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events." | 8.82 | Mitoxantrone treatment of multiple sclerosis: safety considerations. ( Cohen, BA; Mikol, DD, 2004) |
| "Mitoxantrone (MTX) has been shown to reduce progression of disability and number of clinical exacerbations in patients with progressive multiple sclerosis (MS)." | 7.80 | The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. ( Kamińska, AM; Kochanowski, J; Kwieciński, H; Opolski, G; Podlecka-Piętowska, A; Zakrzewska-Pniewska, B, 2014) |
| "Mitoxantrone is an effective disease-modifying therapy in multiple sclerosis (MS), but its use is limited by cardiotoxicity." | 7.79 | Subclinical myocardial dysfunction in multiple sclerosis patients remotely treated with mitoxantrone: evidence of persistent diastolic dysfunction. ( Goggin, C; Joyce, E; Lynch, T; Mahon, N; McGorrian, C; Melling, J; Mulroy, E; O'Rourke, K; Scott, J, 2013) |
| "Mitoxantrone has been extensively used as a disease-modifying therapy for multiple sclerosis." | 7.78 | Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis. ( Goggin, C; Joyce, E; Lynch, T; Mahon, N; Melling, J; Mulroy, E; O'Rourke, K; Scott, J, 2012) |
| "We describe a 30-year-old man with end-stage heart failure after therapy with mitoxantrone for multiple sclerosis." | 7.72 | Heart transplantation in a patient with multiple sclerosis and mitoxantrone-induced cardiomyopathy. ( Castel, MA; Deutsch, O; Nägele, H; Reichenspurner, H; Wagner, FM, 2004) |
| "In a previous dose-finding trial, in previously treated patients with metastatic breast cancer (MBC), we showed that the combination of Mitoxantrone (M) and Paclitaxel (P) may be an interesting (response rate: 69%) and well-tolerated regimen." | 5.11 | Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research. ( Acito, L; Angiona, S; Bilancia, D; Di Costanzo, F; Gasperoni, S; Giustini, L; Manzione, L; Mazzoni, F, 2004) |
| "The review assessed the efficacy and tolerability of mitoxantrone in patients with neuromyelitis optica spectrum disorder (NMOSD)." | 5.01 | Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. ( Enriquez, CAG; Espiritu, AI; Pasco, PMD, 2019) |
| "Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events." | 4.82 | Mitoxantrone treatment of multiple sclerosis: safety considerations. ( Cohen, BA; Mikol, DD, 2004) |
| "Mitoxantrone (MTX) has been shown to reduce progression of disability and number of clinical exacerbations in patients with progressive multiple sclerosis (MS)." | 3.80 | The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. ( Kamińska, AM; Kochanowski, J; Kwieciński, H; Opolski, G; Podlecka-Piętowska, A; Zakrzewska-Pniewska, B, 2014) |
| "Mitoxantrone is an effective disease-modifying therapy in multiple sclerosis (MS), but its use is limited by cardiotoxicity." | 3.79 | Subclinical myocardial dysfunction in multiple sclerosis patients remotely treated with mitoxantrone: evidence of persistent diastolic dysfunction. ( Goggin, C; Joyce, E; Lynch, T; Mahon, N; McGorrian, C; Melling, J; Mulroy, E; O'Rourke, K; Scott, J, 2013) |
| "Mitoxantrone has been extensively used as a disease-modifying therapy for multiple sclerosis." | 3.78 | Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis. ( Goggin, C; Joyce, E; Lynch, T; Mahon, N; Melling, J; Mulroy, E; O'Rourke, K; Scott, J, 2012) |
| "We describe a 30-year-old man with end-stage heart failure after therapy with mitoxantrone for multiple sclerosis." | 3.72 | Heart transplantation in a patient with multiple sclerosis and mitoxantrone-induced cardiomyopathy. ( Castel, MA; Deutsch, O; Nägele, H; Reichenspurner, H; Wagner, FM, 2004) |
| " Immunoblot analysis revealed iNOS protein expression in four out of six failing hearts from septic patients, whereas no iNOS-protein expression was detected in either non-failing human hearts (n = 6) or failing hearts due to IDC (n = 9), ischemic heart disease (IHD, n = 7), Becker muscular dystrophy (BMD, n = 2) and mitoxantrone-induced toxic cardiomyopathy TCM, n = 1)." | 3.69 | Expression of inducible nitric oxide synthase in failing and non-failing human heart. ( Bleese, NM; Förstermann, U; Nüssler, AK; Scholz, H; Stein, B; Thoenes, M; Tracey, WR, 1996) |
| "Sixteen female patients underwent signal-averaged electrocardiography and radionuclide angiography for the assessment of the resting left ventricular ejection fraction in the course of chemotherapy with mitoxantrone (MTX) for advanced breast cancer." | 3.68 | Ventricular late potentials in the assessment of mitoxantrone cardiotoxicity. ( Bartalucci, S; Becucci, A; Cinelli, P; de Leonardis, V; De Scalzi, M; Lottini, G; Neri, B, 1991) |
| "In the following study, patients with acute myeloid leukemia (AML) treated with double induction and consolidation chemotherapy (AML COOP study 1986, [3]) were randomized in a group with and without accompanying low-dose oral verapamil treatment." | 2.67 | Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial. ( Appelt, M; Büchner, T; Eichelbaum, M; Grille, W; Hiddemann, W; Hossfeld, DK; Koslowski, B; Kraft, J; Kuse, R; Quabeck, K, 1990) |
| "However, cardiac failure, the primary cause of death in four patients, was associated with coagulative fiber necroses and contraction band necroses, which may be related to acute cyclophosphamide toxicity." | 1.27 | Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor. ( Dörken, B; Körbling, M; Mall, G; von Herbay, A, 1988) |
| " A dosage of 18 mg/m2 was administered as a short intravenous infusion every 3 weeks." | 1.27 | Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study. ( Etcubanas, E; Krance, RA; Mahoney, DH; Patterson, RB; Pratt, CB; Sexauer, C; Vietti, TJ, 1986) |
| "Mitoxantrone is an anthracenedione derivative with structural and functional similarities to doxorubicin." | 1.27 | Inhibition of endogenous respiration in rat heart slices as a measure of mitoxantrone cardiac toxicity. ( Cini-Neri, G; Neri, B, 1986) |
| "Two percent had congestive heart failure associated with doxorubicin." | 1.27 | Early and delayed clinical cardiotoxicity of doxorubicin. ( Blumenschein, GR; Buzdar, AU; Marcus, C; Smith, TL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (22.73) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 4 (18.18) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Ehrhardt, MJ | 1 |
| Leerink, JM | 1 |
| Mulder, RL | 1 |
| Mavinkurve-Groothuis, A | 1 |
| Kok, W | 1 |
| Nohria, A | 1 |
| Nathan, PC | 1 |
| Merkx, R | 1 |
| de Baat, E | 1 |
| Asogwa, OA | 1 |
| Skinner, R | 1 |
| Wallace, H | 1 |
| Lieke Feijen, EAM | 1 |
| de Ville de Goyet, M | 1 |
| Prasad, M | 1 |
| Bárdi, E | 1 |
| Pavasovic, V | 1 |
| van der Pal, H | 1 |
| Fresneau, B | 1 |
| Demoor-Goldschmidt, C | 1 |
| Hennewig, U | 1 |
| Steinberger, J | 1 |
| Plummer, C | 1 |
| Chen, MH | 1 |
| Teske, AJ | 1 |
| Haddy, N | 1 |
| van Dalen, EC | 1 |
| Constine, LS | 1 |
| Chow, EJ | 1 |
| Levitt, G | 1 |
| Hudson, MM | 1 |
| Kremer, LCM | 1 |
| Armenian, SH | 1 |
| Enriquez, CAG | 1 |
| Espiritu, AI | 1 |
| Pasco, PMD | 1 |
| Joyce, E | 2 |
| Mulroy, E | 2 |
| Scott, J | 2 |
| Melling, J | 2 |
| Goggin, C | 2 |
| McGorrian, C | 1 |
| O'Rourke, K | 2 |
| Lynch, T | 2 |
| Mahon, N | 2 |
| Podlecka-Piętowska, A | 1 |
| Kochanowski, J | 1 |
| Zakrzewska-Pniewska, B | 1 |
| Opolski, G | 1 |
| Kwieciński, H | 1 |
| Kamińska, AM | 1 |
| Dörr, J | 1 |
| Bitsch, A | 1 |
| Schmailzl, KJ | 1 |
| Chan, A | 1 |
| von Ahsen, N | 1 |
| Hummel, M | 1 |
| Varon, R | 1 |
| Lill, CM | 1 |
| Vogel, HP | 1 |
| Zipp, F | 1 |
| Paul, F | 1 |
| Nägele, H | 1 |
| Castel, MA | 1 |
| Deutsch, O | 1 |
| Wagner, FM | 1 |
| Reichenspurner, H | 1 |
| Di Costanzo, F | 1 |
| Manzione, L | 1 |
| Gasperoni, S | 1 |
| Bilancia, D | 1 |
| Acito, L | 1 |
| Angiona, S | 1 |
| Mazzoni, F | 1 |
| Giustini, L | 1 |
| Cohen, BA | 1 |
| Mikol, DD | 1 |
| Pratt, RG | 1 |
| Boehm, GA | 1 |
| Kortepeter, CM | 1 |
| Racoosin, JA | 1 |
| Cavalletti, E | 1 |
| Crippa, L | 1 |
| Mainardi, P | 1 |
| Oggioni, N | 1 |
| Cavagnoli, R | 1 |
| Bellini, O | 1 |
| Sala, F | 1 |
| Bertora, P | 1 |
| Torzillo, D | 1 |
| Baldi, G | 1 |
| Vago, T | 1 |
| Mariani, C | 1 |
| O'Brien, MM | 1 |
| Taub, JW | 1 |
| Chang, MN | 1 |
| Massey, GV | 1 |
| Stine, KC | 1 |
| Raimondi, SC | 1 |
| Becton, D | 1 |
| Ravindranath, Y | 1 |
| Dahl, GV | 1 |
| Domae, N | 1 |
| Kagawa, D | 1 |
| Ueda, T | 1 |
| Goto, M | 1 |
| Tsutani, H | 1 |
| Uchida, M | 1 |
| Nakamura, T | 1 |
| Ando, S | 1 |
| Uchino, H | 1 |
| Thoenes, M | 1 |
| Förstermann, U | 1 |
| Tracey, WR | 1 |
| Bleese, NM | 1 |
| Nüssler, AK | 1 |
| Scholz, H | 1 |
| Stein, B | 1 |
| Johnston, LJ | 1 |
| Stockerl-Goldstein, KE | 1 |
| Hu, WW | 1 |
| Negrin, RS | 1 |
| Hoppe, RT | 1 |
| Blume, KG | 1 |
| Horning, SJ | 1 |
| de Leonardis, V | 1 |
| Bartalucci, S | 1 |
| Cinelli, P | 1 |
| De Scalzi, M | 1 |
| Becucci, A | 1 |
| Lottini, G | 1 |
| Neri, B | 2 |
| Kraft, J | 1 |
| Grille, W | 1 |
| Appelt, M | 1 |
| Hossfeld, DK | 1 |
| Eichelbaum, M | 1 |
| Koslowski, B | 1 |
| Quabeck, K | 1 |
| Kuse, R | 1 |
| Büchner, T | 1 |
| Hiddemann, W | 1 |
| von Herbay, A | 1 |
| Dörken, B | 1 |
| Mall, G | 1 |
| Körbling, M | 1 |
| Pratt, CB | 1 |
| Vietti, TJ | 1 |
| Etcubanas, E | 1 |
| Sexauer, C | 1 |
| Krance, RA | 1 |
| Mahoney, DH | 1 |
| Patterson, RB | 1 |
| Cini-Neri, G | 1 |
| Buzdar, AU | 1 |
| Marcus, C | 1 |
| Smith, TL | 1 |
| Blumenschein, GR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro)[NCT01627938] | Phase 2 | 50 participants (Anticipated) | Interventional | 2012-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for mitoxantrone and Cardiomyopathies
| Article | Year |
|---|---|
Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
Topics: Adolescent; Antibiotics, Antineoplastic; Cardiomyopathies; Child; Humans; Mitoxantrone; Neoplasms; S | 2023 |
Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.
Topics: Cardiomyopathies; Disease Progression; Epidemiologic Studies; Humans; Immunosuppressive Agents; Infe | 2019 |
Mitoxantrone treatment of multiple sclerosis: safety considerations.
Topics: Animals; Cardiomyopathies; Drug Monitoring; Heart Failure; Humans; Immunosuppressive Agents; Leukemi | 2004 |
3 trials available for mitoxantrone and Cardiomyopathies
| Article | Year |
|---|---|
Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Che | 2004 |
Brain natriuretic peptide as a marker of cardiac toxicity in patients with multiple sclerosis treated with mitoxantrone.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Cardiomyopathies; Dose-Response Relationship, Drug; | 2008 |
Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cytarabine; Dau | 1990 |
16 other studies available for mitoxantrone and Cardiomyopathies
| Article | Year |
|---|---|
Subclinical myocardial dysfunction in multiple sclerosis patients remotely treated with mitoxantrone: evidence of persistent diastolic dysfunction.
Topics: Adult; Cardiomyopathies; Diastole; Echocardiography, Doppler; Female; Follow-Up Studies; Humans; Mal | 2013 |
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Topics: Adult; Antineoplastic Agents; Biomarkers; Cardiomyopathies; Female; Heart Diseases; Heart Failure; H | 2014 |
Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
Topics: Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tr | 2009 |
Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis.
Topics: Adult; Aged; Cardiomyopathies; Female; Follow-Up Studies; Humans; Leukemia; Male; Middle Aged; Mitox | 2012 |
Heart transplantation in a patient with multiple sclerosis and mitoxantrone-induced cardiomyopathy.
Topics: Adult; Benzimidazoles; Cardiomyopathies; Cyclosporine; Heart Transplantation; Humans; Immunosuppress | 2004 |
Mitoxantrone treatment of multiple sclerosis: safety considerations.
Topics: Analgesics; Cardiomyopathies; Dose-Response Relationship, Drug; Drug-Related Side Effects and Advers | 2005 |
Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone.
Topics: Animals; Antineoplastic Agents; Cardiomyopathies; Doxorubicin; Drug Interactions; Female; Heart; Iso | 2007 |
Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Child, Preschool; D | 2008 |
[Comparative studies on cardiomyopathy induced in rabbits by various anthracyclines and anthraquinone].
Topics: Animals; Anthraquinones; Antibiotics, Antineoplastic; Cardiomyopathies; Electrocardiography; Heart; | 1984 |
Expression of inducible nitric oxide synthase in failing and non-failing human heart.
Topics: Animals; Cardiomyopathies; Cardiomyopathy, Dilated; Cell Line; Cyclic GMP; Gene Expression; Heart Fa | 1996 |
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bo | 2000 |
Ventricular late potentials in the assessment of mitoxantrone cardiotoxicity.
Topics: Adult; Aged; Breast Neoplasms; Cardiomyopathies; Electrocardiography; Female; Humans; Middle Aged; M | 1991 |
Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Cardiomyopat | 1988 |
Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study.
Topics: Adolescent; Adult; Anthraquinones; Antineoplastic Agents; Cardiomyopathies; Child; Child, Preschool; | 1986 |
Inhibition of endogenous respiration in rat heart slices as a measure of mitoxantrone cardiac toxicity.
Topics: Animals; Anthraquinones; Cardiomyopathies; Heart; In Vitro Techniques; Male; Mathematics; Mitoxantro | 1986 |
Early and delayed clinical cardiotoxicity of doxorubicin.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cyclo | 1985 |